News

List

Download

210831_G-Mendeliome 20CES 20Panel_Flyer_v2.1 List

List

List

List

List

List

List

Download

ESHG 2022 booth 20information.jpg List

Download

medlab booth info_V1.png List

Digital Journal Daily Herald GenomeWeb markets.post-gazette WRDECOAST TV

Celemics signs an agreement to supply BTSeq™ to Sangon Biotech Co., Ltd., a Chinese genetic analysis company

– Successive global expansion following the signing of a supply contract with Tsingke in July
– Wide range of business expectations, such as expansion of high value-added applications and replacement of Sanger sequencing

October 28, 2021, Seoul, Korea: Celemics, Inc. (CEO Young-hoon Lee, Hyo-ki Kim / www.celemics.com), an NGS-based sequencing solution and
bioinformatics tech company, announced on the 28th that it has signed an annual supply agreement of BTSeq™ (Barcode-Tagged Sequencing)
with Sangon Biotech Co., Ltd., located in Shanghai, China.

Sangon, which successfully signed a supply agreement this time, operates 12 subsidiaries throughout China, including in Nanjing and Qingdao,
with the main focus on its headquarters in Shanghai. With annual sales of 164 billion KRW ($ 140.3 million) in 2020, it is considered one of
the most important Sanger Sequencing companies along with Tsingke and BGI. After signing the first global BTSeq™ supply agreement with
Tsingke in July, Celemics signed the second global supply agreement in three months, securing two top Chinese genetic analysis companies as customers,
and solidified its position in China’s NGS market.

In this annual supply agreement, the minimum supply quantity is 100,000 reactions (rxn), and provides both Celemics’s BTSeq™ kits and bioinformatics software
to various service fields operated by Sangon. It was arranged in a short period as it was determined that the technical skills and commercial value of BTSeq™ were
in line with the future strategic direction of Sangon to expand with a high value-added business such as NGS. A company official explained thatas BTSeq™ can be applied to
various application fields, it can also be used to not only develop high value-added NGS application developments, but also replace Sanger sequencing in the existing flagship businesses.

Sangon CEO Wang Gye-song (王啓松) said, “After we set the business direction by expanding high value-added applications, we expect that our new strategy will gain momentum
through BTSeq™’s wide scalability.”

Young-hoon Lee, co-CEO of Celemics, said, “Even when the schedule was delayed due to the coronavirus pandemic, the fact that the contract with Tsingke was executed through
extensive verification procedures serves as a good reference and is receiving a lot of attention from customers. While promoting BTSeq™’s overseas expansion, we have prioritized
the Chinese NGS market, which has the highest global growth potential. I’m glad we had great results. We will do our best to secure our position in other Asian, and Middle Eastern,
and European countries as well.”

List

Download

medica_booth_v1.0.png List

Download

210831_G-Mendeliome CES 20Panel_Flyer_v2.1.pdf List

Celemics signs a supply agreement for BTSeq™ solution with Chinese Sanger sequencing service company

– Celemics enters the Chinese DNA Sequencing market since its establishment
– NGS-based BTSeq™ solution allows for highly accurate DNA sequencing with significantly reduced cost and time
– The agreement scale is equivalent to 87% in celemics’ annual revenue

July.14.2021, Seoul, Korea: Celemics, Inc.(www.celemics.com), an NGS-based sequencing solution and bioinformatics company, Co-CEO Young-hoon Lee and Hyo-ki Kim announced on July 14th
that Celemics has signed an annual supply agreement to provide 4.5 billion KRW ($3.9 million) worth BTSeq™ solution with Tsingke Biological Technology Co., Ltd. (Tsingke), a professional Beijing-based
Sanger sequencing and gene synthesis service company.

The agreement scale is equivalent to 87% of Celemics’ annual sales of 5.2 billion KRW ($4.5 million) in 2020, which is the largest single contract that Celemics has signed since expanding to the
global market in 2017. Celemics will provide BTSeq™ reagents and analysis software, a proprietary genomics analysis platform, in China to Tsingke.

Celemics’ technology supplied to Tsingke with this agreement is BTSeq™ (Barcode Tagged Sequencing) which utilizes NGS technology and Celemics’ proprietary sample preparation reagents and
de novo assembly bioinformatics software. BTSeq™ solution allows for highly accurate DNA sequencing with significantly reduced cost and time. With the conventional method, Sanger sequencing,
the sequencing of a few kb to 20 kb-long DNA takes several days to a few weeks and requires multiple sequencing runs and primer syntheses with high cost. BTSeq™ overcomes these challenges and
enables accurate sequencing of 20 kb-long or longer DNA within 24 hours. With Celemics proprietary reagents and bioinformatics, the cost for NGS-based sequencing and the time required for
analysis is significantly reduced.

Tsingke, Celemics’ Chinese partner for the Chinese genome analysis market, is a professional DNA synthesis and sequencing company established in 2004. Tsingke has 19 subsidiaries in China,
including Beijing, Shanghai and Guangzhou and is a large-scale business proceeding with about 15 million DNA synthesis and sequencing cases annually. Tsingke conducted thorough validation with
various samples in its affiliated companies in Nanjing, Tianjin, etc. to check the BTSeq™ performance and purchased large volume of reagent and analysis software for beta operation.
After about a year of the rigorous validation period, Tsingke decided to introduce Celemics’ BTSeq™ solution.

“We expect to secure exclusive competitiveness in DNA synthesis and sequencing service with the new Celemics’ sequencing technology, BTSeq™, and will pioneer diverse application markets with Celemics.”
‘Tsingke CEO Ma Shijin’

“Celemics is delighted to enter the Chinese NGS market through scrupulous examinations, which reassure the competitiveness of BTSeq™. Celemics will take this contract as a stepping stone to expand
our contribution for researchers and companies in the fast-growing Chinese DNA sequencing market with 1.4 billion population.”
‘Celemics Co-Founder & CEO Hyoki Kim’

Meanwhile, Celemics has been continuously and successfully preparing to expand to the global market. Celemics has recently completed designating distributors in countries such as Spain, Portugal,
United Arab Emirate (UAE) and Japan and concluded partnership arrangements with distinguished international companies.

List

Genomeweb EINPRESSWIRE

Celemics, South Dakota State University, announce partnership for the development of Hybridization NGS-based Multiple Swine Pathogen Co-Detection Panel.

– The proposed methods are seen as a revolutionary step towards preventing swine respiratory diseases

July 07, 2021, Seoul, Korea: Celemics, Inc.(www.celemics.com) has partnered with South Dakota State University’s Animal Disease Research and Diagnostic Laboratory (ADRDL) to create the first-ever hybridization-based
next generation sequencing (NGS) kit to detect viral and bacterial swine respiratory pathogens.

Most current diagnostic technologies are based on culture or qPCR. These widely used methods come with a great amount of limitations in terms of detecting a wide range of pathogens. The new and proposed breakthrough technique
can make it possible to detect several viral and bacterial pathogens at once.

Celemics Inc. is known for its innovative and ground-breaking research. It was the need of the hour to alter the paradigm of medicine for swine respiratory diagnosis and treatment. It is hoped that their much-welcomed partnership with
the esteemed South Dakota State University will bring revolutionary methods for early detection and cure to the industry.
Until this point in time, the genetic characterization, including whole genome sequence information for viral pathogens and multi-locus sequencing typing (MLST) analysis for bacterial pathogens, is attained through pathogen detection methods.
This joint venture of research between the two reputed names has given them hope for improved overall herd health outcomes. The technology aims to overcome the shortfalls of modern diagnostics by enabling highly multiplexed detection
and sequence characterization.
Not only would this be more efficient but considerably cost-effective in comparison to the existing practices.

We spoke to Mr. Benjamin Hause, Assistant Professor in the Department of Veterinary and Biomedical Sciences, about this promising prospect:
“We are pleased to partner with Celemics on developing and bringing this exciting new technology to the swine industry,” ‘Celemics’ hybridization panel represents a large leap forward in our ability to detect and concurrently
genetically characterize swine pathogens.
While we focus on the most significant pathogens such as porcine reproductive and respiratory syndrome virus and influenza A virus, clinical disease is often the end result of co-infections with a number of viruses and bacteria.
Celemics’ technology will enable comprehensive pathogen screening that will allow better herd management and improved swine health.”
The technology aims to overcome the shortfalls of modern diagnostics by enabling highly multiplexed detection and sequence characterization. Not only would this be more efficient but considerably cost-effective in comparison to the existing practices.

The kit results from years of remarkable research and comprises more than 50 different viral and bacterial swine pathogens. All of these sequences have been carefully chosen based on the study of patterns that are relevant to swine health
and include domestically critical species such as the porcine reproductive and respiratory syndrome virus (PRRSV) and influenza A virus, along with foreign viruses such as African swine fever virus (ASFV) and foot and mouth disease virus.
“With this new partnership, we hope to provide clinicians, veterinarians, and livestock breeders with a powerful, comprehensive tool for swine disease detection and prevention,” said co-CEO and founder of Celemics, Dr. Hyoki Kim.

Through the advantages of hybridization NGS, we hope to provide a kit capable of revolutionizing clinical research and diagnostics and hope to effectively combat future swine disease epidemics.

List